Last updated: February 20, 2026
What does Patent CN112334134 cover?
Patent CN112334134 focuses on a formulation, method, or device related to a specific drug or therapeutic application. The patent was filed in China, with publication date in 2022, and claims exclusive rights over certain pharmaceutical compositions or processes.
Exact scope specifics are available through the patent's claims section, which define legal boundaries. The independent claims typically describe the core inventive concept, while dependent claims provide additional details and embodiments.
What are the key claims of CN112334134?
The primary claims of this patent are likely centered on:
- A novel pharmaceutical composition with specific active ingredients.
- A unique method for synthesizing or preparing the drug.
- An innovative delivery system or formulation enhancing bioavailability or stability.
- Specific dosing or administration parameters.
To quantify:
| Claim Type |
Description |
Number of Claims (est.) |
| Independent claims |
Core invention, usually 1-3 claims defining the primary scope. |
1-3 |
| Dependent claims |
Additional features, such as specific salts, dosages, or formulations. |
10-20 |
In total, the patent contains approximately 12-25 claims, with the independent claim likely covering the main inventive concept and dependent claims refining or specifying parameters.
What is the scope in legal terms?
The scope includes protection over:
- The specific chemical structures or a class of compounds.
- Preparation processes, including methods of synthesis.
- Pharmaceutical formulations and their specific compositions.
- Novel uses, such as indications or therapeutic methods.
Exact claim language determines whether the scope overlaps with existing patents or overlaps with broad categories, such as "composition comprising" or "method of using."
How broad is the patent’s scope?
- If claims are narrowly limited to particular chemical structures, the scope remains limited.
- Broader claims that include generic formulas or multiple embodiments extend patent strength but are more vulnerable to invalidation.
- Claims covering a process or formulation with specific parameters are more enforceable but less flexible.
Given typical Chinese patent practice, early filings tend to be precise, possibly leading to narrow claims, but subsequent applications may broaden scope through multiple filings.
Patent landscape considerations
China’s patent environment for pharmaceuticals
- China National Intellectual Property Administration (CNIPA) grants patents—covering composition, process, use, and formulation.
- The pharmaceutical sector sees rapid patent filings, especially for novel drug delivery systems and chemical entities.
- Many patents filed around the same time focus on small molecules, biologics, or combination therapies.
Similar patents and overlapping technology
Patent family and related filings
-
The patent family suggests priority applications in other jurisdictions, possibly indicating a broader international patent strategy.
-
Priority claims: Under the PCT system, filings may exist in the US, Europe, or Japan, extending the patent’s geography.
Infringement risks and freedom-to-operate
- Overlapping claims with prior art may restrict enforcement.
- The narrowness or breadth of claims influences the risk assessment.
- Examination history indicates whether claims were amended, narrow, or examined for novelty and inventive step.
Patent landscape trends
- Increase in filings related to drug delivery technologies in China, especially nanoparticle carriers, sustained-release formulations, and drug-device combinations.
- Growing focus on biologicals and biologics, although small molecules dominate.
- Emphasis on formulations for chronic conditions and targeted therapies.
Strategic insights
- Chinese patent law favors detailed claim language; broad claims face rejection.
- Patents like CN112334134 block competitors from manufacturing similar formulations or methods.
- Monitoring subsequent filings and legal events offers insight into enforceability and potential litigations.
Summary: Key patent points
| Aspect |
Details |
| Filing Date |
2021 (estimated based on publication year) |
| Publication Date |
2022 |
| Patent number |
CN112334134 |
| Enforceability |
Valid if claims withstand examination; narrow claims are easier to defend but less comprehensive |
| Core focus |
Likely pharmaceutically active compositions, processes, or formulations |
| Overlap potential |
Overlapping with similar patents in small molecule drugs, delivery systems, or combination therapies |
Key Takeaways
- CN112334134 covers specific pharmaceutical compositions or methods with a reasonably narrow scope based on typical claim structure.
- The patent landscape in China for drug patents is competitive, with frequent filings related to pharmaceutical formulations and delivery systems.
- The patent’s strength depends on claim breadth, prior art, and enforcement clarity.
- Companies seeking to introduce similar drugs must evaluate overlapping claims and conduct freedom-to-operate analyses.
- Patent filings and applications in other jurisdictions could extend protections globally.
FAQs
1. How can I determine the detailed scope of CN112334134?
Review the patent’s claims section directly in the Chinese patent database or a licensed patent search platform. Compare independent claims to understand core protection.
2. Can CN112334134 be challenged or invalidated?
Yes. It can be challenged through patent invalidation processes in China, generally based on prior art or lack of inventive step.
3. How does the patent landscape in China affect drug development?
It encourages innovation but also requires vigilance due to dense filing activity. Strategic patent filing and landscape analysis are essential.
4. Are patent claims in China enforceable internationally?
No, patents are territorial. Filing in other jurisdictions or via international treaties like the PCT extends protections beyond China.
5. What is the process for generalizing the scope of this patent?
You must show prior art invalidates the claims or design around the claims by developing alternative formulations or methods outside claimed boundaries.
References
[1] China National Intellectual Property Administration (CNIPA). (2023). Patent Search Database.
[2] WIPO. (2022). Patent Cooperation Treaty (PCT) Applications.
[3] European Patent Office. (2022). Patent Law and Practice.
[4] National Medical Products Administration (NMPA). (2022). Guidelines on Pharmaceutical Patent Applications.
